Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
15 October 2019 | Story Valentino Ndaba | Photo Valentino Ndaba
Mental health awareness
The UFS joined the global community in commemorating World Mental Health Day.

“This is not a conversation that should wait until people have taken their own lives or have been diagnosed,” said Tshepang Mahlatsi, Founder of Next Chapter, a student organisation that advocates for mental health. In commemoration of World Mental Health Day, the organisation hosted a dialogue around this year’s theme of Mental Health Promotion and Suicide Prevention on 10 October 2019.

Mahlatsi further said: “The conversation around mental health is not one that should be reserved for September or October when we commemorate suicide prevention and World Mental Health Day. We should build a culture and tradition of having and normalising these conversations. This notion becomes highly relevant at institutions of higher learning where most students are affected by various factors, such as finances and academic anxiety.”

Dealing with the dilemma

This open discussion took place on the Bloemfontein Campus between students and a panel comprising Dr Ntswaki Setlaba and Dr Melissa Barnaschone.

Dr Setlaba, a consultant psychiatrist at Pelonomi Tertiary Hospital, said one of the symptoms of major depressive disorder is suicide. She highly recommends that early detection of depression is essential in order to prevent it escalating to a loss of more lives.

Director of the Office for Student Counselling and Development, Dr Barnaschone, supported the concept of early detection, citing that there are plans put in place to support students, such as workshops and the Student Mental Health Toolkit.

Medicine of the mind

Dr Fanie Meyer, a private psychiatrist based in Bloemfontein, described to staff members the effects of depression and anxiety on the brain. He presented a talk titled: Pain vs Depression: ‘The chicken or the egg?’ which was hosted by the Organisational Development and Employee Wellness division in collaboration with the Faculty of Health Sciences.

He also stressed the importance of early detection. “If you leave your pain running for 10 years, it will get worse. The same goes for anxiety,” said Dr Meyer. 

According to Burneline Kaars, Head of the Division, they are committed to changing attitudes about mental health and reducing the stigma experienced by those who live with it. “The focus is on educating staff about mental illness and empowering them to take action and promote mental wellbeing while it is still early.”  

Recognising the early symptoms of a mental disorder is an essential part of tackling the pandemic. Having the mental health conversation throughout the year instead of in September and October ought to further this agenda. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept